

Nxera Pharma

FY2025 Financial Results

12-month period ended December 31, 2025

13 February 2026 | Nxera Pharma Co., Ltd. (TSE: 4565)



Disclaimer

The material that follows is a presentation of general background information about Nxera Pharma Co., Ltd and its subsidiaries (collectively, the "Company") as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third-party evaluation of any securities or any offering of them and should not be considered as a recommendation that any recipient should subscribe for or purchase any securities.

The information contained herein is in summary form and does not purport to be complete. Certain information has been obtained from public sources. No representation or warranty, either express or implied, by the Company is made as to the accuracy, fairness, or completeness of the information presented herein and no reliance should be placed on the accuracy, fairness, or completeness of such information. The Company takes no responsibility or liability to update the contents of this presentation in the light of new information and/or future events. In addition, the Company may alter, modify or otherwise change in any manner the contents of this presentation, in its own discretion without the obligation to notify any person of such revision or changes.

This presentation contains "forward looking statements," as that term is defined in Section 27 A of the U S Securities Act of 1933 as amended, and Section 21 E of the U S Securities Exchange Act of 1934 as amended. The words "believe", "expect", "anticipate", "intend", "plan", "seeks", "estimates", and "and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. These factors include, without limitation, those discussed in our public reports filed with the Tokyo Stock Exchange and the Financial Services Agency of Japan. Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonably based on information currently available to the Company's management, certain forward-looking statements are based upon assumptions of future events which may not prove to be accurate. The forward-looking statements in this document speak only as at the date of this presentation and the company does not assume any obligations to update or revise any of these forward statements, even if new information becomes available in the future.

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Recipients of this presentation are not to construe the contents of this summary as legal, tax or investment advice and recipients should consult their own advisors in this regard.

This presentation and its contents are proprietary confidential information and may not be reproduced, published or otherwise disseminated in whole or in part without the Company's prior written consent. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This presentation contains non-GAAP financial measures. The non-GAAP financial measures contained in this presentation are not measures of financial performance calculated in accordance with IFRS and should not be considered as replacements or alternatives profit, or operating profit, as an indicator of operating performance or as replacements or alternatives to cash flow provided by operating activities or as a measure of liquidity (in each case, as determined in accordance with IFRS). Non-GAAP financial measures should be viewed in addition to, and not as a substitute for, analysis of the Company's results reported in accordance with IFRS.

(c) Nxera Pharma Co, Ltd, 2024. Nxera and the Nxera logos are trademarks of Nxera Pharma Co. Ltd.



Agenda

- 01 Financial Results
- 02 Operational Highlights
- 03 Japan /APAC Commercial Business
- 04 R&D Progress
- 05 FY2026 Objectives and beyond
- 06 Appendix



Financial Results


Hironoshin Nomura, CFO

01



Key financial results

While the commercial business grew, milestones decreased year-on-year, resulting in a core operating loss



Progress in 2025



- Multiple milestone receipts from Neurocrine, Centessa, Lilly, AbbVie, etc.
- Down YoY due to the absence of the prior-year large M4 agonist Phase 2 success milestone



- 39% revenue growth (YoY)
 - Pivlaz: +7% YoY
 - Quviviq: +224% YoY



- R&D spend up in platform business on progress across three in-house clinical
- SG&A down in commercial business, driven by Pivlaz sales cost decrease



Breakdown of 2025 results

Strong profitability growth in the commercial business; accelerated clinical-trial investment in the platform business

(JPY million)	Platform* ¹	Commercial* ²		Consolidated P&L (Core)		Non-core costs		Consolidated P&L (IFRS)	(YoY)
	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	
Revenue	10,207	-31%	19,408	+39%	29,615	+3%	Total : 8,110	29,615	+3%
Cost of Sales	2,111	-22%	6,022	+149%	8,133	+59%	A Amortization (1,789)	8,198	+8%
SG&A	4,940	+15%	5,480	-16%	10,420	-4%	B Other (3,080)	15,225	-5%
R&D	11,669	+26%	1,352	+9%	13,022	+24%	B Other (1,444)	14,466	+22%
Other income	1,615	+344	(7)	+15	1,608	+360	C (1,797)	(189)	-1,377
OP/Core OP	(6,899)	-6,745	6,547	+2,787	Core OP (352)	-3,958		OP (8,462)	-3,038

A Amortization of intangible assets (currently relates to PIVLAZ® and QUVIVIQ®).

B Amortization of other intangible assets (e.g. IP), depreciation (e.g. laboratory equipment), share-based payments and other restructuring costs.

C Restructuring costs and impairment losses


*1 = Nxera Pharma Co. Ltd. (formerly Sosei Group Corporation) + Nxera Pharma UK Ltd (formerly Heptares Therapeutics Ltd.) + Sosei K.K. (ex -Nxera Pharma Basel branch)

*2 = Nxera Pharma Japan (formerly Idorsia Pharmaceuticals Japan) + Nxera Pharma Korea (formerly Idorsia Pharmaceuticals Korea) + Nxera Pharma Basel branch



Analysis of changes in R&D expenses

Clinical Development and Increased Investment Focus on Obesity as Key Drivers of Growth



~

Operational Highlights

Chris Cargill, President and CEO

02



Recap of FY2025 Priority Objectives

01

JPY 17 billion+ Net product sales
(PIVLAZ® plus QUVIVIQ®)



JPY17.8Bn

02

Acquire/in-license at least one late-stage medicine for Japan/APAC (ex-China)



Vamorolone
In-licensing (Jan)

03

Execute at least one new major partnership, and initiate at least one new in-house Ph.2 study



EP4 Antagonist
Initiation of Ph2

04


Investment in systems and applications for efficiency and scalability



Investment
Executed as planned

05

Positive operating profit under IFRS
(if GPR52 option is exercised)



Profit missed as
option not exercised



Both sides of the business continue to advance rapidly

Drug Discovery Platform



Clinical Asset

Active Programs Changes in 2025

Phase 3

2*

+2

Phase 2

5

+2

Phase 1

5

-3 (moved to Ph2)

Major Partners



abbvie

Lilly



Pfizer

Commercial



Products

2025 Sales (Actual : JPY) Changes in 2025 (Actual : JPY)

PIVLAZ®

13.5Bn

+7%

QUVIVIQ®

4.3 Bn

+224%

Late-stage assets

Vamorolone

New

Candidate drug for DMD. Already approved in US and Europe.

Lucerastat




Candidate drug for Fabry disease. Nxera has exclusive opt-in rights.

On track to continue growth trajectory throughout 2026



Commercial Business

Two marketed products continue to grow, with a new product launch in early 2026 to support the next phase



A “practical guide to clazosentan administration” is scheduled for release in the first half of 2026

Shionogi will be responsible for sales.
Nxera hold the rights to product supply and royalties

Potential to replace existing steroid therapy
Estimated sales synergy with Pivlaz® of ~70%



Platform Business

Partner-led development progressing well; strong phase 1 readouts for in-house programs



Muscarinic Agonist Portfolio

Program	Target Disease	Phase
Direclidine	Schizophrenia	Phase3
	Bipolar disorder	Phase2
NBI'570	Schizophrenia	Phase2
NBI'569	AD's Psychosis	Phase1
NBI'567	AD	Phase1
	LBD	

First phase 3 readout for
direclidine expected in 2027

Royalty: high single digits to mid-teens;
Total milestones: up to \$2.6bn

Lead asset cobenfry peak sales
expected to exceed JPY600bn



Orexin Agonist Portfolio

Program	Target Disease	Phase
ORX750	NT1/NT2/IH	Phase2
ORX142	Neurological disorders	Phase2
ORX489	Neurological disorders	-

ORX750 to enter a registrational
program in 1H 2026

Royalty: low single digits
Development and sales milestones

ORX750 peak sales expected
to exceed ¥200bn

GPR52 ago | EP4 ago

Licensing activities in progress

Program	Target Disease	Phase
NXE'149	Schizophrenia	Phase1
NXE'744	IBD	Phase1

Phase 1 completed successfully
Phase 2 ready to initiate

In discussions with multiple
partners for a 2026 license deal

NXE'744 showed early efficacy signals
in an indomethacin challenge study

EP4 antag

Under development in-house

Program	Target Disease	Phase
NXE'732	Solid Cancer	Phase2

Ongoing phase 2 readout for
NXE'732 expected in 2027

Nxera retains global rights

NXE'732 showed early efficacy signals,
including two partial responses





Major Pipeline Overview

Discovery – Preclinical → Phase1 → Phase2 → Phase3 → Filed → Commercial



Vamorolone
Duchenne Muscular Dystrophy

Lucerastat
Fabry disease

PIVLAZ®
Cerebral vasospasm

QUVIVIQ™
Insomnia



IN-HOUSE

Best-in-class,
focused on obesity
and metabolic
diseases

EP4 ag. NXE'744
IBD

GPR52 ag. NXE'149
Schizophrenia

EP4 ant. NXE'732
Advanced solid tumors



Develop programs in-house up to a certain stage to enhance their value, then out-license them to partner companies—while retaining rights for Japan (and other territories) for selected indications.



PARTNERED

Key discovery
collabs



Diabetes/Metabolic



Neurology

M₁M₄ ag. NBI'569
Alzheimer's psycho

NEUROCRINE
BIOSCIENCES

M₁ ag. NBI'567
AD Cognition*/LBD

NEUROCRINE
BIOSCIENCES

M₄ ag. NBI'568
Bipolar Mania

NEUROCRINE
BIOSCIENCES

M₄ ag. NBI'568
Schizophrenia

NEUROCRINE
BIOSCIENCES

M₁M₄ ag. NBI'570
Schizophrenia

NEUROCRINE
BIOSCIENCES

OX2 ag. ORX750
Narcolepsy, IH

CENTESSA
PHARMACEUTICALS

OX2 ag. ORX142
Neurology

CENTESSA
PHARMACEUTICALS

MC4 ant. PF'669
Malnutrition



Other

Cenerimod
SLE



Respiratory Portfolio
COPD / Asthma



Japan/APAC Commercial Business


Toshihiro Maeda, Chief Operating Officer (COO) and
President of Nxera Pharma Japan

03



PIVLAZ® (clazosentan, an endothelin A antagonist)

Our first commercially available product for the prevention of cerebral vasospasm in patients with Aneurysmal Subarachnoid Haemorrhage (aSAH)



2025 PIVLAZ® highlights

- ✓ **25,470** patients were treated by PIVLAZ® since the launch to Dec 2025.
- ✓ **103** abstracts were presented at annual congress of STROKE2025
- ✓ Academic society drafted "Practical Guide to the Administration of Clazosentan", which would be published in Mar-2026

Pivlaz® is now the clear Standard of Care (SoC) in Japan




QUVIVIQ® (daridorexant, dual orexin antagonist “DORA”)

DORA is rapidly establishing its position in the treatment paradigm for insomnia




Domestic Market Size for DORA



QUVIVIQ® Annual Sales and Growth Rate

5.0 – 6.0 Bn JPY






QUVIVIQ® Business structure

Royalty profits initiated and supply margin expected in a few years




Sales structure

Product net sales



Profit structure for Nxera



Supply chain optimization

Comprehensive strategy to optimize the end-to-end supply chain

Achievements as of today

- ✓ Establish Nxera independent supply chain from the licensor
- ✓ Regulatory approval on 2nd API source in October

Future plan

- ✓ Achieve further cost optimization on raw materials
- ✓ Optimize drug product and packaging sourcing

Announced: In-licensing of vamorolone (AGAMREE®) for DMD

There is no established therapy for DMD other than corticosteroids in Japan


Vamorolone (AGAMREE®)

- First-in-class drug candidate that binds to the **same receptors as corticosteroids** but modifies the downstream activity of the receptors
- Nxera has the development rights for **Japan, South Korea, Australia and New Zealand**
- DMD treatment is concentrated in a limited number of centers and there is approximately **70% sales synergy with PIVLAZ®**



Duchenne Muscular Dystrophy (DMD)

- DMD is a rare and life-threatening neuromuscular disorder
- Characterized by progressive muscle dysfunction leading to ambulation loss, respiratory failure, heart issues and premature death
- No efficacious therapy apart from corticosteroids, however they present many severe adverse events





Vamorolone (AGAMREE®) addresses the need for a tolerable steroid

Compared with conventional corticosteroid therapy, the risk of treatment-related adverse events is reduced




- Vamorolone confronts the limitations of standard corticosteroid therapy
- Topline data from the recent GUARDIAN clinical study showed **durable efficacy** and **markedly improved safety** of vamorolone vs. standard corticosteroids
- Study demonstrated reduction of steroid-associated adverse events related to:
 - Growth – *normal growth maintained (p<0.0001)*
 - Bone health – *lower vertebral fracture rate (p=0.0061)*
 - Eye health – *lower incidence of cataracts (p<0.015) and no cases of glaucoma*
- Reduction of side effects allows patients **to maintain treatment**

Consensus sales forecast of vamorolone in other countries

(mUSD)

North America (by Catalyst)
Europe (by Santhera)






Synergy with Pivlaz



DMD treatment is concentrated in a limited number of centers and there is approximately 70% commercial overlap with PIVLAZ, creating significant sales synergies





R&D Progress

Dr. Patrik Foerch, Chief Scientific Officer (CSO) and President of Nxera Pharma UK


04



Renewed R&D focus where the science is strongest and the opportunity is greatest



IN-HOUSE PORTFOLIO - R&D FOCUS AND PROGRAM PRIORITISATION




R&D focus on highest potential opportunities

NXE'744: EP4 agonist for IBD* – target engagement & Phase 2 ready

A first-in-class GI-targeted agent to promote mucosal healing in IBD

EP4 AGONIST OFFERS A DIFFERENTIATED MOA TO CURRENT SOC:

Modulation of barrier homeostasis and inflammatory axis positions EP4 as an attractive MOA for IBD therapy



*inflammatory bowel disease

- All elements of the first-in-human study have now completed dosing in the clinic

- SAD/MAD studies are complete with no concerning adverse events and no systemic exposure observed
- Gut restricted profile confirmed by high gut tissue concentrations measured following oral dosing
- UC patient cohort has completed dosing (n=6) with interim analysis confirming high gut tissue concentration.
- Indomethacin challenge cohort complete, interim analysis complete with no need to increase subjects and final data read-out by March 2026
- Preliminary data analysis demonstrates a highly significant ~50% reduction in indomethacin induced permeability in the NXE'744 treatment group; these data confirm target engagement in the small intestine

Study link:

<https://www.isrctn.com/ISRCTN70080074?q=nxera&filters=&sort=&offset=1&totalResults=2&page=1&pageSize=10>



NXE'149: GPR52 agonist for schizophrenia – Phase 2 ready

A novel first-in-class mechanism to treat positive, negative & cognitive domains of schizophrenia




Phase 1 highlights:

- ✓ Safe and well tolerated
- ✓ Human PK showed low variability and consistent with once daily dosing
- ✓ High level of central penetration
- ✓ Pharmacodynamic measures provide evidence of engagement of brain circuitry relevant to the treatment of schizophrenia and related disorders

Phase 2 enablement:

- 3 month GLP toxicology in 2 species
- 2 species EFD completed
- Metabolite characterisation complete
- Drug substance and drug product available for phase 2 start

SAD PK data



EEG and ERP measures

- NXE'149 clearly engages frontotemporal circuitry underlying the MMN and ASSR responses, both of which are reproducible biomarkers in schizophrenia
- Resting state EEG data suggest increased arousal on day 10 of treatment

Cognition

Cogstate assessment demonstrated improvements in cognitive performance across doses on day 10 of treatment

General cognitive composite	Dose 1	Dose 2	Dose 3	Dose 4
Attention/Executive Function	0.89	1.5	0.69	0.64
General Cognition	1.1	0.84	0.77	0.55

Standardized differences between each dose of NXE'149 compared to placebo

NXE'732: EP4 antagonist is our novel immunotherapy for solid tumors

Phase 2a expansion in process in combination with atezolizumab





Disease Rationale

- When EP4 is activated, it dampens immune responses and promotes tumor growth
- EP4 antagonism is a highly attractive mechanism supported by recent clinical data for ONO-4578 in gastric cancer
- NXE-732 is designed to deliver **high potency, selectivity, and safety**

Phase 1 trial results


- The emerging data for NXE-732 points to a potential best-in-class profile
- Two partial responses were observed in MSS CRC and anti-PD-L1 resistant ccRcc in the combination arm, with meaningful tumor shrinkage of over 30% demonstrated
- Target engagement confirmed and no dose-limiting toxicities Combo Mono




Phase 2a expansion study underway in **MSS Colorectal** (PIK3CA, HER2± others), **Gastric/GOJ Adenocarcinoma, Renal (ccRCC), Prostate (CRPC)**

We can make a huge impact by leveraging our GPCR expertise in the areas of highest unmet medical need: next-generation small molecules for obesity, metabolic and endocrine disorders

Unparalleled GPCR SBDD capabilities



Structure of GLP1-R
bound to **peptide**



Structure of GLP1-R
bound to **small molecule**


- **Launched broad new pipeline**, advancing next-gen BIC therapies for obesity and metabolic disorders
- **Convenient, scalable oral therapies** for sustained weight loss in a market dominated by peptides
- **Targeting key obesity-related co-morbidities**: Enhanced outcomes in cardiovascular, renal, and liver diseases
- **Reducing side effects** and **broadening** out to difficult to treat populations

MECHANISM	Nxera
GLP-1 ag	
GIP ant	
Amylin ag	
Multiple other targets of interest	

Nxera aims to redefine obesity, weight management and related co-morbidities by delivering potent, oral small molecules to meet a critical global need at scale



Neurocrine is advancing the world's most comprehensive portfolio of muscarinic agonists to treat neuropsychiatric disorders



Program	Mechanism	Disease State	Stage of Development
Direclidine	M4 Agonist	Schizophrenia	Phase 3
		Bipolar Mania	Phase 2
NBI-570	Dual M1/M4 Agonist	Schizophrenia / LAI Potential	Phase 2
NBI-569	Dual M1/M4 Agonist	Alzheimer's Psychosis	Entering Phase 1b
		Alzheimer's Cognition	Phase 1
NBI-567	M1 Preferring Agonist	Lewy Body Dementia	

Five clinical-stage programs spanning the M1, M4, and dual M1/M4 mechanisms designed using NxWave™



Centessa is advancing ORX750, a potential best-in-class Orexin Receptor 2 agonist for treatment of NT1, NT2 and IH



Potential BIC for NT1, NT2 and IH

ORX750

CRYSTAL-1 Phase 2a study in NT1, NT2 and IH



Evaluate safety, tolerability, and PK in NT1, NT2, and IH patients

Efficacy assessment registrational endpoints: **Maintenance of Wakefulness Test (MWT)**, **Epworth Sleepiness Scale (ESS)**, **weekly cataplexy rate** (NT1 patients only), and overall symptom improvement*

Exploratory efficacy assessments will measure sleep, **cognition, attention, memory**, and general health

First robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across NT1, NT2 and IH...

- ✓ **Generally favorable safety and tolerability profile**
- ✓ **Statistically significant, clinically meaningful and dose-dependent efficacy**
- ✓ **Dose escalation** across ongoing and future cohorts with **once-daily and split-dose regimens**, enabled by Phase 1 data

...Expect to initiate registration program in Q1 2026

Phase 2a study update

Endpoints

Maintenance of Wakefulness Test (MWT)	>20 min change at 1.5mg vs baseline (with half of participants >30 min). NT1 >10 min change at 4mg vs baseline. NT2
---------------------------------------	---

Epworth Sleepiness Scale (ESS)	1.5mg = 5.1 vs 18.7 (placebo). NT1 4mg = 8.1 vs 15.9 (placebo). NT2
--------------------------------	--

Weekly Cataplexy Rate (WCR)	87% relative reduction at 1.5mg vs placebo. NT1
-----------------------------	---

Participants	55 participants (NT1, NT2 & IH)
--------------	---------------------------------

Next step	Registrational Program initiation planned for Q1 2026
-----------	---

Initial Phase 2a data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; **Expect to initiate registrational program in Q1 2026**



FY2026 Objectives and beyond

Chris Cargill, President and CEO

05



Priority objectives for FY2026

01

JPY 19.5 billion+ Net product sales
(PIVLAZ® plus QUVIVIQ®)



02

Get one or more late-stage assets
for Japan and APAC (excl. China)



03

Sign one or more high-value partnership deals



04

Initiate at least one partner-sponsored phase 2 trial



05


Reduce total costs by >10% and
achieve full-year profitability on IFRS basis





Historical financial and 2026 guidance (Without significant upfront from BD activity)

Target profitability for both Core Operating Profit and Operating Profit in FY26



FY26 Strategy



- Multiple milestones to be received from Neurocrine, Centessa, Lilly, AbbVie, etc.
- Plan to out-license priority programs, including GPR52 agonist and EP4 agonist



- Pivlaz: +5% YoY
- Quviviq: +30% YoY



- Rationalize investment in clinical-stage assets and focus funding on obesity & metabolic programs
- Pursue margin maximization in the commercial business



Breakdown of 2026 guidance (Without significant upfront from BD activity)

Commercial business profitability has grown significantly. Platform business has reached breakeven on a core basis

(JPY million)		Platform* ¹		Commercial* ²		Consolidated P&L (Core)		Non-core costs		Consolidated P&L (IFRS)	
		(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)	(YoY)
Revenue		14,300	+40%	19,500	+0%	33,800	+14%	Total : 7,100		33,800	+14%
Cost of Sales		1,400	-34%	5,700	-5%	7,100	-13%	A Amortization (1,800)		7,200	-12%
SG&A*³		5,700	+15%	3,700	-32%	9,400	-10%	B Other (3,100)		14,200	-7%
R&D*³		8,100	-31%	2,400	+78%	10,500	-19%	B Other (1,500)		12,000	-17%
Other income		1,000	-615	-	+7	1,000	-608	(700)		300	+489
OP/Core OP		100	+6,999	7,700	+18%	Core OP 7,800	+8,152			OP 700	+9,162

A Amortization of intangible assets (currently relates to PIVLAZ® and QUVIVIQ®).

B Amortization of other intangible assets (e.g. IP), depreciation (e.g. laboratory equipment), share-based payments and other restructuring costs.

*1 = Nxera Pharma Co. Ltd. (formerly Sosei Group Corporation) + Nxera Pharma UK Ltd (formerly Heptares Therapeutics Ltd.) + Sosei K.K. (ex -Nxera Pharma Basel branch)

*2 = Nxera Pharma Japan (formerly Idorsia Pharmaceuticals Japan) + Nxera Pharma Korea (formerly Idorsia Pharmaceuticals Korea) + Nxera Pharma Basel branch

*3 = We expect the effects of restructuring initiatives implemented since Nov 2025 to become more evident in the 2H26



Looking ahead to potential catalysts in 2026*


PROGRAM	PARTNER	TIMING	EVENT	
ORX750 (OX2 agonist)	 CENTESSA PHARMACEUTICALS	Q1 2026	Phase 2a data across NT1, NT2, and IH	
ORX750 (OX2 agonist)	 CENTESSA PHARMACEUTICALS	Q1 2026	Registrational program start in NT1/NT2/IH	
ORX142 (OX2 agonist)	 CENTESSA PHARMACEUTICALS	Q1 2026	Phase 2 study start	
ORX489 (OX2 agonist)	 CENTESSA PHARMACEUTICALS	Q1 2026	Phase 1 study start	
NBI'570 (M1/M4 ago)	 NEUROCRINE BIOSCIENCES	Q1 2026	Phase 2 study start	
Multiple discovery collaboration progress	 abbvie <i>Lilly</i>	1H 2026	Progression through discovery stage	
Cenerimod	 VIATRIS	Q4 2026	Phase 3 data readout	
NBI'567 (M1 ago) / NBI'569 (M1/M4 ago)	 NEUROCRINE BIOSCIENCES	2H 2026	Clinical progression	
PF'669 (MC4 antagonist)	 Pfizer	2026	Phase 1 data readout	
NBI'567 (M1 ago) / NBI'569 (M1/M4 ago) / NBI'570 (M1/M4 ago)	 NEUROCRINE BIOSCIENCES	2026	Phase 1 data disclosure	
New global out-licenses		Anytime	Out licensing and/or discovery collabs	
New Japan / APAC in-licenses		Anytime	Acquire/in-license late-stage medicines	
QUVIVIQ™ / Vamorolone		Anytime	APAC out-licensing deals	

* Partnered product progress is as already signaled or disclosed by partner



Our 2030 vision is to build a high growth, highly profitable Japanese biopharma

JPY Bn



Note: * Revenue values are proforma the acquisition of Idorsia Pharmaceuticals Japan and Korea and reflect annual product sales of PIVLAZ in 2023.

** WAVE1 and WAVE2 royalty is not included.

~

Questions?

~

Thank you



BREAKTHROUGHS IN PROGRESS • BREAKTHROUGHS IN PROGRESS • BREAKTHROUGHS IN PROGRESS



Locations



Midtown East,
9-7-2 Akasaka
Minato-ku
Tokyo 107-0052

Japan



F17, 410 Teheran-
Ro
GangHam-Gu
Seoul 06192

South Korea



Steinmetz Building
Granta Park,
Cambridge
CB21 6DG

United Kingdom



Spaces Grosspeter
Tower,
Grosspeteranlage
29,
4052 Basel

Switzerland